Clinical Trial Update: CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial compares CD19 CAR-T cell therapy to donor lymphocyte infusion for MRD-positive Philadelphia chromosome-negative acute lymphoblastic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19 CAR-T cell therapy (CAR-T cell therapy targeting CD19)
• Donor Lymphocyte Infusion

Snippet

Sponsor: Peking University People's Hospital | Conditions: B ALL, Allogenetic Hematopoietic Stem Cell Transplantation | Phase 3 | Status: RECRUITING